These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
4. Pathogen-reduced platelets for the prevention of bleeding. Butler C; Doree C; Estcourt LJ; Trivella M; Hopewell S; Brunskill SJ; Stanworth S; Murphy MF Cochrane Database Syst Rev; 2013 Mar; (3):CD009072. PubMed ID: 23543569 [TBL] [Abstract][Full Text] [Related]
5. New strategies for the optimal use of platelet transfusions. Blajchman MA; Slichter SJ; Heddle NM; Murphy MF Hematology Am Soc Hematol Educ Program; 2008; ():198-204. PubMed ID: 19074082 [TBL] [Abstract][Full Text] [Related]
6. Safety and cost effectiveness of a 10 x 10(9)/L trigger for prophylactic platelet transfusions compared with the traditional 20 x 10(9)/L trigger: a prospective comparative trial in 105 patients with acute myeloid leukemia. Wandt H; Frank M; Ehninger G; Schneider C; Brack N; Daoud A; Fackler-Schwalbe I; Fischer J; Gäckle R; Geer T; Harms P; Löffler B; Ohl S; Otremba B; Raab M; Schönrock-Nabulsi P; Strobel G; Winter R; Link H Blood; 1998 May; 91(10):3601-6. PubMed ID: 9572994 [TBL] [Abstract][Full Text] [Related]
7. Comparison of the Hemostatic Efficacy of Pathogen-Reduced Platelets vs Untreated Platelets in Patients With Thrombocytopenia and Malignant Hematologic Diseases: A Randomized Clinical Trial. Garban F; Guyard A; Labussière H; Bulabois CE; Marchand T; Mounier C; Caillot D; Bay JO; Coiteux V; Schmidt-Tanguy A; Le Niger C; Robin C; Ladaique P; Lapusan S; Deconinck E; Rolland C; Foote AM; François A; Jacquot C; Tardivel R; Tiberghien P; Bosson JL; JAMA Oncol; 2018 Apr; 4(4):468-475. PubMed ID: 29392283 [TBL] [Abstract][Full Text] [Related]
8. The impact of platelet transfusion characteristics on posttransfusion platelet increments and clinical bleeding in patients with hypoproliferative thrombocytopenia. Triulzi DJ; Assmann SF; Strauss RG; Ness PM; Hess JR; Kaufman RM; Granger S; Slichter SJ Blood; 2012 Jun; 119(23):5553-62. PubMed ID: 22496156 [TBL] [Abstract][Full Text] [Related]
9. Background, rationale, and design of a clinical trial to assess the effects of platelet dose on bleeding risk in thrombocytopenic patients. Slichter SJ J Clin Apher; 2006 Apr; 21(1):78-84. PubMed ID: 16619231 [TBL] [Abstract][Full Text] [Related]
10. Eltrombopag for advanced myelodysplastic syndromes or acute myeloid leukaemia and severe thrombocytopenia (ASPIRE): a randomised, placebo-controlled, phase 2 trial. Mittelman M; Platzbecker U; Afanasyev B; Grosicki S; Wong RSM; Anagnostopoulos A; Brenner B; Denzlinger C; Rossi G; Nagler A; Garcia-Delgado R; Portella MSO; Zhu Z; Selleslag D Lancet Haematol; 2018 Jan; 5(1):e34-e43. PubMed ID: 29241762 [TBL] [Abstract][Full Text] [Related]
11. What is the proper threshold for platelet transfusion in patients with chemotherapy-induced thrombocytopenia? Benjamin RJ; Anderson KC Crit Rev Oncol Hematol; 2002 May; 42(2):163-71. PubMed ID: 12007974 [TBL] [Abstract][Full Text] [Related]
12. Bleeding risks are higher in children versus adults given prophylactic platelet transfusions for treatment-induced hypoproliferative thrombocytopenia. Josephson CD; Granger S; Assmann SF; Castillejo MI; Strauss RG; Slichter SJ; Steiner ME; Journeycake JM; Thornburg CD; Bussel J; Grabowski EF; Neufeld EJ; Savage W; Sloan SR Blood; 2012 Jul; 120(4):748-60. PubMed ID: 22538854 [TBL] [Abstract][Full Text] [Related]
14. Do all patients with hematologic malignancies and severe thrombocytopenia need prophylactic platelet transfusions? Background, rationale, and design of a clinical trial (trial of platelet prophylaxis) to assess the effectiveness of prophylactic platelet transfusions. Stanworth SJ; Dyer C; Choo L; Bakrania L; Copplestone A; Llewelyn C; Norfolk D; Powter G; Littlewood T; Wood EM; Murphy MF; Transfus Med Rev; 2010 Jul; 24(3):163-71. PubMed ID: 20656185 [TBL] [Abstract][Full Text] [Related]
16. Therapeutic efficacy of platelet transfusion in patients with acute leukemia: an evaluation of methods. Apelseth TO; Bruserud O; Wentzel-Larsen T; Hervig T Transfusion; 2010 Apr; 50(4):766-75. PubMed ID: 20030789 [TBL] [Abstract][Full Text] [Related]
17. Comparison of efficacy of low and high dose prophylactic platelet transfusion therapy in thrombocytopenic haemato-oncology patients. Dhiman Y; Hans R; Sharma RR; Malhotra P; Marwaha N Transfus Apher Sci; 2020 Feb; 59(1):102610. PubMed ID: 31345687 [TBL] [Abstract][Full Text] [Related]
18. Different Platelet Count Thresholds to Guide Use of Prophylactic Platelet Transfusions for Patients With Hematological Disorders After Myelosuppressive Chemotherapy or Stem Cell Transplantation. Estcourt LJ; Stanworth SJ; Murphy MF JAMA Oncol; 2016 Aug; 2(8):1091-2. PubMed ID: 27415031 [TBL] [Abstract][Full Text] [Related]
19. Hemostatic efficacy of pathogen-inactivated vs untreated platelets: a randomized controlled trial. van der Meer PF; Ypma PF; van Geloven N; van Hilten JA; van Wordragen-Vlaswinkel RJ; Eissen O; Zwaginga JJ; Trus M; Beckers EAM; Te Boekhorst P; Tinmouth A; Lin Y; Hsia C; Lee D; Norris PJ; Goodrich RP; Brand A; Hervig T; Heddle NM; van der Bom JG; Kerkhoffs JH Blood; 2018 Jul; 132(2):223-231. PubMed ID: 29773572 [TBL] [Abstract][Full Text] [Related]
20. Platelet Transfusion before CVC Placement in Patients with Thrombocytopenia. van Baarle FLF; van de Weerdt EK; van der Velden WJFM; Ruiterkamp RA; Tuinman PR; Ypma PF; van den Bergh WM; Demandt AMP; Kerver ED; Jansen AJG; Westerweel PE; Arbous SM; Determann RM; van Mook WNKA; Koeman M; Mäkelburg ABU; van Lienden KP; Binnekade JM; Biemond BJ; Vlaar APJ N Engl J Med; 2023 May; 388(21):1956-1965. PubMed ID: 37224197 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]